PROVIREX Genome Editing Therapies GmbH’s Post

Do data from clinical trials translate into real world evidence? An overwhelming YES from the ELEVATE pivotal study which once again shows the transformative benefit of chronic LVAD support in Advanced Heart Failure - A median survival in excess of 5 years, a tripling in 6 minute walk distance and near doubling in QOL achieved. Adding life to years and not just years to life. The findings are also echoed by the recent INTERMACS real world analysis (Ann Thorac Surg. 2023 Nov 8:S0003-4975(23)01155-4.). We MUST move to better implementation of the findings of these studies by proving these life saving opportunities to our patients. Finn Gustafsson Javed Butler Prof. Dr. J. D. Schmitto, MD, PhD, MBA, FRCS(Glasg) FACS Arjang Ruhparwar Daniel Goldstein, MD Manreet Kanwar Andrew J. Sauer, MD Robert Kormos

The promising results of Donanemab in the TRAILBLAZER-ALZ 2 phase III trial spotlight a new ray of hope in slowing Alzheimer’s progression. Dive into our latest article to explore the groundbreaking findings. #Donanemab #ClinicalTrial #AlzheimersResearch. Read it here: https://lnkd.in/gvBA2MAN

What are the current management options, algorithms and recommendations for treatment of myeloid blast phase CML? Gain insights into this rare condition’s progression, as Professor Mhairi Copland summarises recent studies and clinical trials, and explores combination therapies and novel therapy options that are currently being assessed. Learn more about Myeloid-BP CML in the iCMLf Knowledge Centre here: https://bit.ly/47CsCX4

Bruce Ellsworth, PhD, and Aryeh Fischer, MD, discuss drug discovery and potential new advances in treating #PulmonaryFibrosis in this Q&A. We understand the challenges faced by individuals living with pulmonary fibrosis, as breathlessness can greatly impact their daily lives. That's why we remain committed to pursuing pathbreaking science that may help patients in need. Read the full article here: https://bit.ly/3ywHlFS #ATS2024

A systematic review for the radiotherapeutic approach of Ventricular arrhythmias. Stereotactic arrhythmia radioablation as an alternative treatment approach has several fields of discussion and research originating from the current clinical study outcomes. https://lnkd.in/dzzpXKZ2

Join us this afternoon at 4:00 PM EST for an insightful session. Our distinguished speakers will delve deep into the significance of this groundbreaking observational trial. Don't miss this opportunity to be part of a pivotal discussion shaping the future of psychedelic-assisted therapies RSVP Here: https://bit.ly/47dNpQ9 #webinar #psychedelics #mdma #mdxx #psychedelicscience

Our Head of Diagnostics, T. Scott Reid, explores the importance of Companion Diagnostics in our latest Science Hub blog. From the birth of CDx to the most recent challenges, learn how CDx are developed and approved through clinical trials and how data-driven approaches are poised to streamline the process and enhance access to precision medicine. Read the blog: https://ter.li/v8obvy #PrecisionMedicine #CompanionDiagnostics #ClinicalTrials

Join us in honoring all the researchers, clinicians, and trial participants who contribute to the advancement of medicine on this #ClinicalTrialsDay. Your tireless efforts bring us one step closer to a healthier future. Our DurAVR™ THV First-in-Human and Early Feasibility Study clinical trials have allowed us to continuously refine and improve our transcatheter heart valve system to treat patients with aortic stenosis. We are rigorously testing our products and preparing for a larger pivotal clinical trial poised to lead to market approval. Learn more about our current clinical data here: https://lnkd.in/gvMsnjRM Christopher Meduri, Anita Asgar, Azeem Latib, Edwin Ho, Andreas Scotti, Stanley Chetcuti, Gorav Ailawadi, MD, MBA, P Michael Grossman, Sinichi Fukuhara, Maia Zhividze, Rishi Puri, Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Vinayak Bapat, Tamaz Shaburishvili, Teona Zirakashvili

Survodutide (GLP1RA/GCGRA) achieves primary endpoint in Ph2 clinical trial. -- Top-line result: ➡ 83% improvement in biopsy-proven MASH❗ https://lnkd.in/gEGRe5vH